1. 肝细胞癌免疫治疗中 国专家共识,2021年, 013;华医学杂志2021 年12月28日第101 卷第48期 2. Hyuna Sung, Jacques Ferlay, Rebecca L. Siegel, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. ACS journals. 2021, 71(3):209-249 3. CSCO原发性肝癌诊疗指 335;,2020年, 中国临床肿瘤学会指 南工作委员会,人民 卫生出版社
1. Capurro M, Wanless IR, Sherman M, et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology. 2003; 125:89-97. 2. Kolluri A and Ho M. The Role of Glypican-3 in Regulating Wnt, YAP, and Hedgehog in Liver Cancer. Front. Oncol. 2019, 9:708.
[1] ALLEMANI C, WEIR HK, CARREIRA H, et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25, 676, 887 patients from 279 population-based registries in 67countries (CONCORD-2) . Lancet, 2015, 385: 977-1010. [2] TORRE LA, BRAY F, SIEGEL RL, et al. Global cancer statistics, 2012. CA Cancer J Clin, 2015, 65: 87-108.